Navigation Links
Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy

SAN MARINO, Calif., May 4 /PRNewswire/ -- Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled "Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer" (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA. What the reader will gain: In recording the development of Rexin-G as a novel targeted biological therapy, this review also highlights important aspects of vector engineering which served to overcome the physiological barriers to gene delivery as it addresses the key regulatory issues involved in the development of a targeted gene therapy product. Take home message: Progressive clinical development of Rexin-G demonstrates the potential safety and efficacy of targeted genetic medicine in otherwise intractable cancers, while validating the design engineering of the molecular biotechnology platform.

The second article, entitled "Noteworthy Clinical Case Studies in Cancer Gene Therapy" (Intl. J. Oncology, April, 2010) highlights important aspects of Rexin-G bio-pharmacology, as this tumor-targeted vector advances as an efficacious anti-cancer agent. What the reader will gain: These remarkable case studies, in and of themselves, reveal important aspects of the molecular pharmacology, advanced clinical protocols, refinement of patient monitoring, expanding treatment options, and strategic medical approaches to patient care that exemplify and thereby extend the established principles of pathotropic targeting and cancer gene therapy to a new generation of clinical practitioners. Take home message:  Each case study, in an otherwise intractable cancer, "teaches" a vital lesson in the emerging praxis of cancer control.

Finally, the third article comes in the form of a Minireview entitled "Nanoparticles and the Immune System" (Endocrinology, Feb, 2010) co-authored by members of the FDA Center for Drug Evaluation and Research, Office of Pharmaceutical Science, and the Nanotechnology Characterization Laboratory of the National Cancer Institute. What the reader will gain: This astute review of medical nanotechnology aptly describes the concept of targeted delivery of Rexin-G followed by Reximmune-C as a two-tier complementary approach aimed at both tumor eradication and personalized cancer vaccination. That is, the first step involves the use of Rexin-G to target and control the progression of metastatic cancer, whereas the second step employs Reximmune-C to induce a localized cancer immunization. Take home message: This is a commendable and timely review of these first-in-class, best-in-class tumor-targeted anti-cancer agents, which may supersede more cumbersome approaches to personalized cancer vaccinations.

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. To learn more about our recent publications and/or proprietary biotechnologies, visit .  

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Epeius Biotechnologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
2. Epeius Biotechnologies to Partner at BIO Investor Forum
3. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
4. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
5. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
6. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
7. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
8. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
9. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
10. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
11. Glycos Biotechnologies Expands Management Team with Appointment of Vice President of Research and Development
Post Your Comments:
(Date:10/9/2015)... , ... October 09, 2015 , ... ... However, the current methods of separating those cells from their surroundings for research, ... to the cells. , To address this, Ann Arbor-based startup Akadeum Life ...
(Date:10/8/2015)... WEST PALM BEACH, Fla. , Oct. 8, 2015 ... a leader in synthetic biology, today announced the appointment ... President, Head of Environment Sector, succeeding Nir Nimrodi ... Corporate Development.  Mr. Vaillancourt will direct Intrexon,s endeavors to ... North America , where he held ...
(Date:10/8/2015)... 8, 2015  ATCC, the premier global biological materials ... been selected by The Michael J. Fox Foundation for ... academic, pharmaceutical, and biotechnology organizations committed to speed a ... United States , and more than 5 million ... United States , and more than 5 million ...
(Date:10/8/2015)... , October 8, 2015 ...   --> Goldman Small Cap Research, ... small cap and microcap sectors, announced today that ... on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a ... developing and preparing treatments for cancer and diabetes. ...
Breaking Biology Technology:
(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
(Date:9/29/2015)... News facts: ... energy , Minimized design shrinks PC footprint ... and embedded Fujitsu PalmSecure authentication enable enterprises to realize ... shows that good things come in small packages, with ... enterprise desktop and mobile portfolio. Featuring workplace design that ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
Breaking Biology News(10 mins):